Despite this heterogeneity, prostate tumor growth is, almost always, dependent upon the androgen receptor (AR) pathway [2,3,4], explaining the efficacy of androgen deprivation therapies (ADT) or anti-androgens for the treatment of hormone-naïve PCa [5,6]. This evidence concerns the gene AR and prostate neoplasm.